Biointron’s Post

𝐍𝐞𝐰! 𝐒𝐦𝐚𝐥𝐥-𝐒𝐜𝐚𝐥𝐞 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐄𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐏𝐚𝐜𝐤𝐚𝐠𝐞𝐬! Biointron offers a new choice for your small-scale antibody expression rush needs. 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐑𝐮𝐬𝐡𝐌𝐚𝐛® : 💡 𝐃𝐞𝐬𝐢𝐠𝐧𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐜𝐨𝐬𝐭-𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐚𝐧𝐝 𝐭𝐢𝐦𝐞-𝐬𝐚𝐯𝐢𝐧𝐠 ⚡ 𝐀𝐬 𝐟𝐚𝐬𝐭 𝐚𝐬 𝟖 𝐝𝐚𝐲𝐬 🧪 𝐌𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝟓,𝟎𝟎𝟎 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 🔍 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐬𝐜𝐚𝐥𝐞𝐬 𝐟𝐫𝐨𝐦 𝐒𝐮𝐩𝐞𝐫, 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝, 𝐚𝐧𝐝 𝐌𝐢𝐧𝐢 Now adding 𝐑𝐮𝐬𝐡𝐌𝐚𝐛® - 𝐆𝐞𝐧𝐞, with 100 ug transfection grade expression plasmids ready in only 4 days! For more details, visit our website: https://lnkd.in/gbgdjSYe Contact us at [email protected] or +1 (732) 790-8340, or DM our LinkedIn homepage RIGHT NOW! #Biointron #Antibodyexpression #antibodydiscovery #antibodytherapeutics #purifiedantibody #antibodyproduction

Find the antibody for your project, explore Biointron's rich antibody product portfolio, and take advantage of our 40% sitewide discount! 🎁 Save on your project with Biointron! Click here 👉 https://lnkd.in/eSw3_Qpa ☀ 𝐁𝐞𝐧𝐜𝐡𝐦𝐚𝐫𝐤 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 🔎 𝐈𝐬𝐨𝐭𝐲𝐩𝐞 𝐍𝐞𝐠𝐚𝐭𝐢𝐯𝐞 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 🐭 𝐀𝐧𝐭𝐢-𝐌𝐨𝐮𝐬𝐞 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 ✅ 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 ...and more! #Biointron #Abinvivo #reagents #invivo #antibodies #proteins

🌟 𝐎𝐮𝐫 𝐥𝐚𝐭𝐞𝐬𝐭 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐝𝐞𝐥𝐯𝐞𝐬 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐚𝐬 𝐭𝐨𝐨𝐥𝐬 💡 At Biointron, we specialize in antibody production and discovery – dedicating ourselves to advancing human health and promoting sustainability with more than 10 years of experience and over 1500 customers globally. We offer premium solutions at competitive rates, all anchored in our commitment to a brighter and healthier future. Read the article here: https://lnkd.in/dFFXaY6d #Biointron #Antibodies #Abinvivo #DrugDiscovery #Research

𝟏 𝐌𝐨𝐧𝐭𝐡 𝐓𝐢𝐥𝐥 𝐁𝐈𝐎 𝐉𝐚𝐩𝐚𝐧 𝟐𝟎𝟐𝟒! The Biointron team will be waiting for you at Yokohama! 📅 Date: October 9-11, 2024 📍 Location: Pacifico Yokohama | Yokohama, Japan 🔬 Booth #D-28 Schedule a 1-on-1 meeting spot with our expert team. Let's discuss how we can accelerate your projects! 🔗 https://lnkd.in/g-miu5-h #Biointron #BioJapan #BIO #biotech #antibody #lifescience

⚡ 𝐇𝐢𝐠𝐡𝐭-𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭 𝐅𝐮𝐥𝐥𝐲 𝐇𝐮𝐦𝐚𝐧 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐢𝐧 𝟑 𝐌𝐨𝐧𝐭𝐡𝐬! ⏳Experience the unparalleled 𝐀𝐛𝐃𝐫𝐨𝐩™ timeline from Biointron: Millions of plasma B cells are screened - 𝟏 𝐷𝐴𝑌 NGS sequencing & data analysis - 𝟏 𝑊𝐸𝐸𝐾 Hundreds of naturally paired heavy & light chains are obtained - 𝟏 𝑇𝐼𝑀𝐸 From screening to purified antibodies with validated activity - 𝟏 𝑀𝑂𝑁𝑇𝐻 Learn more about this at our website: 🔗 https://lnkd.in/gDzW6SrM Or contact us 📞 +1(732)790-8340 | 📩 [email protected] Let's discuss how we can accelerate your antibody discovery! #Biointron #Cyagen #humanantibody #antibodydiscovery #singlebcell

A recent review describes practical insights into AI-accelerated therapeutic antibody development 🤖 Recent Artificial Intelligence (AI) breakthroughs have enabled information-rich in silico representations of antibodies, accurate prediction of antibody structure from sequence, and the generation of novel antibodies tailored to specific characteristics to optimize for developability properties. The review highlights key AI models like Antibody Language Models (ALMs) and folding models, showing how they improve the efficiency of antibody discovery while emphasizing practical considerations like model licenses for industry application. Despite progress, challenges remain, especially in addressing solubility and viscosity due to limited experimental data. AI’s integration in drug development holds promise for faster, more cost-effective therapeutic innovations. Read the full paper here 👉 https://lnkd.in/eVBUe4W7 #Biointron #Antibodies #AI #DrugDevelopment #DrugDiscovery #Technology Study by Luca Santuari et al.

#BiointronWeeklyReports Read our recap of this week’s news in the antibody industry!    #Biointron #Antibodies #Immunotherapy #PharmaNews #DrugDevelopment 

Explore Abinvivo, a Biointron brand dedicated to providing antibodies for in vivo research! 🎯 Enjoy an 𝐞𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝟒𝟎% 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐬𝐢𝐭𝐞𝐰𝐢𝐝𝐞 on all products, valid until December — perfect for boosting your research project. 🔗https://lnkd.in/eSw3_Qpa 🌟 Benchmark Positive Antibody 🔍 Isotype Negative Antibody 🐭 Anti-Mouse Antibody ✅ Bispecific Antibody …and much more to elevate your research, with 𝐨𝐧𝐥𝐢𝐧𝐞 𝐜𝐡𝐞𝐜𝐤𝐨𝐮𝐭 𝐚𝐧𝐝 𝟏-𝐰𝐞𝐞𝐤 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲! #Biointron #Abinvivo #reagents #invivo #antibodies #proteins

Read on for a recap of the World Bispecifics Summit 2024 👇 𝟏. 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 • CLDN18.2 x 4-1BB bispecific: anti-4-1BB VHH that targets the membrane proximal region can be further optimized with unidirectional Fc effector function towards TAAs. (Biotheus Inc.)  • ABBV-383: a novel bispecific antibody with enhanced tumor targeting & optimized t-cell engagement in multiple myeloma. (AbbVie)  • Endogenous T cell reactivities as drivers of TCE response & resistance (leveraging TCE immune perturbations to establish predictive biomarkers and novel personalized cell therapies). (Broad Institute of MIT and Harvard Institute)   𝟐. 𝐀 𝐍𝐞𝐰 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐈𝐦𝐦𝐮𝐧𝐞 𝐂𝐞𝐥𝐥 𝐄𝐧𝐠𝐚𝐠𝐞𝐫𝐬 • Solving the combinatorial matrix puzzle and fast-tracking bispecific generation for early-stage functional assessment through multiparametric, high throughput in silico-driven molecular optimization to derisk programs as early as possible. (IPA (ImmunoPrecise Antibodies)) • There is growing evidence of T-cell engagers with clinical benefit for solid tumors, not just in hematological malignancies. (Amgen) • Selectively activating subsets of T cells present in tumor-infiltrating lymphocytes of solid tumors to promote more potent anti-tumor activity by uncovering associations between Vβ T cell subsets and diseases. (Marengo Therapeutics) 𝟑. 𝐋𝐚𝐭𝐞𝐬𝐭 𝐍𝐨𝐯𝐞𝐥 𝐅𝐨𝐫𝐦𝐚𝐭𝐬 • XmAb541: 2+1 CLDN6 x CD3 bispecific has two tumor-antigen binding domains and one T-cell binding domain, to treat ovarian cancer & other CLDN6+ solid tumors. (Xencor) • Azymetric platform used to optimally format T-cell engagers & bispecific ADCs with a robust Fc heterodimer solution. E.g. Zanidatamab, a bi-paratopic anti-HER2 antibody undergoing clinical studies. (Zymeworks Inc.) • FAST-Ig platform used to produce bispecific antibodies and improve antibody pharmacokinetics. E.g. NXT007, a next-gen version of emicizumab for hemophilia A. (Chugai Pharma USA, Inc.) • Overcome tolerability challenges with bispecifics targeting CD47 on tumor cells and regulate CD28-mediated T-cell co-stimulation, overcoming tolerability challenges while avoiding systemic toxicities associated with CD47 and CD28 targeting, respectively. (Light Chain Bioscience | Novimmune SA) Read the full recap here: https://lnkd.in/ecNZmcNx #Biointron #Antibodies #Immunotherapy #PharmaNews #DrugDevelopment #Bispecific #ClinicalTrials #Innovation #Networking

⚡ 𝐀 𝐍𝐞𝐰 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐟𝐨𝐫 𝐅𝐮𝐥𝐥𝐲 𝐇𝐮𝐦𝐚𝐧 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲! ⏳Experience the unparalleled 𝐀𝐛𝐃𝐫𝐨𝐩™ timeline from Biointron: Millions of plasma B cells are screened in 𝟏 𝐷𝐴𝑌 NGS sequencing & data analysis in 𝟏 𝑊𝐸𝐸𝐾 Hundreds of naturally paired heavy & light chains are obtained at 𝟏 𝑇𝐼𝑀𝐸 From screening to purified antibodies with validated activity in 𝟏 𝑀𝑂𝑁𝑇𝐻 Learn more about this at our website: 🔗 https://lnkd.in/gDzW6SrM Or contact us 📞 +1(732)790-8340 | 📩 [email protected] Let's discuss how we can accelerate your antibody discovery! #Biointron #Cyagen #humanantibody #antibodydiscovery #singlebcell